Christopher DeJesus

Chris previously worked as a Senior Scientist within Tiaki Therapeutics developing small molecule therapies targeting chronically inflamed microglia present in neurodegenerative diseases. Tiaki developed a novel organotypic culture platform that recapitulated inflammatory hallmarks present in AD, HD, and ALS. Chris received his M.S. and Ph.D. from the Albert Einstein College of Medicine, where he focused on neural stem cell biology and epigenetics.